ESR1 and cancer: Moreover, Patel and colleagues [252] have shown that elacestrant exhibits anti-cancer activity in the cells resistant to all CDK4 and 6 inhibitors approved to date, namely palbociclib, abemaciclib, and ribociclib in both wild-type and mutated ESR1.